A clinical trial conducted by Stanford Medicine found that a 15-day course of Paxlovid, an antiviral drug for COVID-19, was safe but did not improve symptoms of long COVID. The trial did not show that Paxlovid reduced long COVID symptoms, but it demonstrated that the drug could be taken safely for an extended period. The study explored the viral-reservoir hypothesis of long COVID and found no significant benefit in the treatment. Researchers are now analyzing data to understand individual responses to Paxlovid and how it may impact long COVID symptoms. The trial did not provide clear evidence of Paxlovid’s effectiveness for long COVID.
Source link
Clinical trial shows 15-day Paxlovid regimen safe but adds no clear benefit for long COVID
